An expert discusses how the phase 3 LUNA 3 trial demonstrated that rilzabrutinib achieved durable platelet responses in 23% of patients while also being the first prospective trial to show significant ...

(RTTNews) - Sanofi - Aventis Groupe said results from the LUNA 3 phase 3 study showed that rilzabrutinib 400 mg twice daily orally achieved the primary endpoint of durable platelet response in adult ...

Trying to cut through the noise surrounding beauty tech is a tough one. Back in the day, a jade roller was the most high-tech skincare tool you could have in your arsenal, but now we’ve got devices ...

Los Angeles, CA /PRNewswire/ - RuggON, an international maker of ruggedized mobile solutions, today introduced its latest fully rugged tablet, the 8" LUNA 3. Featuring an eco-friendly design, it is ...